tiprankstipranks
Boston Scientific (IT:1BSX)
:1BSX
Italy Market
1BSX
Boston Scientific
RESEARCH TOOLSreports

Boston Scientific (1BSX) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

1BSX Analyst Ratings

Strong Buy
24Ratings
Strong Buy
21 Buy
3 Hold
0 Sell
Based on 24 analysts giving stock ratings to
Boston
Scientific
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1BSX Stock 12 Month Forecast

Average Price Target

€54.21
▲(32.21% Upside)
Based on 24 Wall Street analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is €54.21 with a high forecast of €77.30 and a low forecast of €43.43. The average price target represents a 32.21% change from the last price of €41.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"36":"€36","50":"€50","64":"€64","78":"€78","92":"€92"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":77.30445482,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€77.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.207873579090894,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€54.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.429469,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€43.43</span>\n  </div></div>","useHTML":true}}],"tickPositions":[36,50,64,78,92],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.195,42.12649652461538,45.057993049230774,47.98948957384616,50.92098609846154,53.852482623076924,56.78397914769231,59.7154756723077,62.64697219692308,65.57846872153846,68.50996524615385,71.44146177076924,74.37295829538462,{"y":77.30445482,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.195,40.34983642916084,41.504672858321676,42.659509287482514,43.81434571664335,44.96918214580419,46.12401857496503,47.278855004125866,48.433691433286704,49.58852786244754,50.74336429160838,51.89820072076922,53.053037149930056,{"y":54.207873579090894,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.195,39.52072838461538,39.84645676923077,40.17218515384615,40.49791353846154,40.82364192307692,41.14937030769231,41.47509869230769,41.80082707692308,42.12655546153846,42.45228384615385,42.77801223076923,43.10374061538461,{"y":43.429469,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":91.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 86,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 97,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.645,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 88,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.145,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.84,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.195,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€77.30Average Price Target€54.21Lowest Price Target€43.43
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on IT:1BSX
Anthony Petrone
Mizuho Securities
Mizuho Securities
€60.8→€52.12
Buy
27.11%
Upside
Reiterated
07/31/26
Mizuho Securities Remains a Buy on Boston Scientific (BSX)
Citi Analyst forecast on IT:1BSX
Joanne Wuensch
Citi
Citi
€52.12→€52.98
Buy
29.23%
Upside
Reiterated
07/31/26
Boston Scientific: Buy Rating Reaffirmed as Analyst Trims Price Target to $61 but Sees Strong Long-Term Growth Reacceleration
Argus Research Analyst forecast on IT:1BSX
David Toung
Argus Research
Argus Research
―
Hold
―
Downgraded
07/30/26
Boston Scientific downgraded to Hold from Buy at ArgusBoston Scientific downgraded to Hold from Buy at Argus
Deutsche Bank Analyst forecast on IT:1BSX
Pito Chickering
Deutsche Bank
Deutsche Bank
€65.14→€52.12
Buy
27.11%
Upside
Reiterated
07/30/26
Deutsche Bank Remains a Buy on Boston Scientific (BSX)
Truist Financial Analyst forecast on IT:1BSX
Richard Newitter
Truist Financial
Truist Financial
€53.85→€49.51
Buy
20.76%
Upside
Assigned
07/30/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and The Ensign Group (NASDAQ: ENSG)
Oppenheimer Analyst forecast on IT:1BSX
Suraj Kalia
Oppenheimer
Oppenheimer
€73.83
Buy
80.07%
Upside
Reiterated
07/30/26
Oppenheimer Keeps Their Buy Rating on Boston Scientific (BSX)
Leerink Partners Analyst forecast on IT:1BSX
Mike Kratky
Leerink Partners
Leerink Partners
€64.28→€52.12
Buy
27.11%
Upside
Reiterated
07/30/26
Boston Scientific price target lowered to $60 from $74 at LeerinkBoston Scientific price target lowered to $60 from $74 at Leerink
J.P. Morgan Analyst forecast on IT:1BSX
Robbie Marcus
J.P. Morgan
J.P. Morgan
€69.49→€48.64
Buy
18.64%
Upside
Assigned
07/30/26
Boston Scientific price target lowered to $56 from $80 at JPMorganBoston Scientific price target lowered to $56 from $80 at JPMorgan
Evercore ISI Analyst forecast on IT:1BSX
Vijay Kumar
Evercore ISI
Evercore ISI
€56.46→€47.77
Buy
16.52%
Upside
Reiterated
07/30/26
Boston Scientific price target lowered to $55 from $65 at Evercore ISIBoston Scientific price target lowered to $55 from $65 at Evercore ISI
Robert W. Baird Analyst forecast on IT:1BSX
David Rescott
Robert W. Baird
Robert W. Baird
€55.59→€48.64
Buy
18.64%
Upside
Reiterated
07/30/26
Boston Scientific price target lowered to $56 from $64 at BairdBoston Scientific price target lowered to $56 from $64 at Baird
TD Cowen Analyst forecast on IT:1BSX
Josh Jennings
TD Cowen
TD Cowen
€52.98→€48.64
Buy
18.64%
Upside
Reiterated
07/30/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC) and Boston Scientific (NYSE: BSX)
Canaccord Genuity Analyst forecast on IT:1BSX
William Plovanic
Canaccord Genuity
Canaccord Genuity
€60.8→€57.33
Buy
39.82%
Upside
Reiterated
07/30/26
Boston Scientific price target lowered to $66 from $70 at CanaccordBoston Scientific price target lowered to $66 from $70 at Canaccord
UBS Analyst forecast on IT:1BSX
Patrick Wood
UBS
UBS
€64.28→€58.2
Buy
41.94%
Upside
Reiterated
07/30/26
Morgan Stanley Reaffirms Their Buy Rating on Boston Scientific (BSX)
Needham Analyst forecast on IT:1BSX
Michael Matson
Needham
Needham
€49.51
Buy
20.76%
Upside
Reiterated
07/29/26
Analysts Offer Insights on Healthcare Companies: Rezolute (NASDAQ: RZLT) and Boston Scientific (NYSE: BSX)
Wells Fargo Analyst forecast on IT:1BSX
Larry Biegelsen
Wells Fargo
Wells Fargo
€47.77→€43.43
Hold
5.93%
Upside
Reiterated
07/29/26
Analysts Are Neutral on Top Healthcare Stocks: Boston Scientific (BSX), Capricor Therapeutics (CAPR)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on IT:1BSX
Anthony Petrone
Mizuho Securities
Mizuho Securities
€60.8→€52.12
Buy
27.11%
Upside
Reiterated
07/31/26
Mizuho Securities Remains a Buy on Boston Scientific (BSX)
Citi Analyst forecast on IT:1BSX
Joanne Wuensch
Citi
Citi
€52.12→€52.98
Buy
29.23%
Upside
Reiterated
07/31/26
Boston Scientific: Buy Rating Reaffirmed as Analyst Trims Price Target to $61 but Sees Strong Long-Term Growth Reacceleration
Argus Research Analyst forecast on IT:1BSX
David Toung
Argus Research
Argus Research
―
Hold
―
Downgraded
07/30/26
Boston Scientific downgraded to Hold from Buy at ArgusBoston Scientific downgraded to Hold from Buy at Argus
Deutsche Bank Analyst forecast on IT:1BSX
Pito Chickering
Deutsche Bank
Deutsche Bank
€65.14→€52.12
Buy
27.11%
Upside
Reiterated
07/30/26
Deutsche Bank Remains a Buy on Boston Scientific (BSX)
Truist Financial Analyst forecast on IT:1BSX
Richard Newitter
Truist Financial
Truist Financial
€53.85→€49.51
Buy
20.76%
Upside
Assigned
07/30/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and The Ensign Group (NASDAQ: ENSG)
Oppenheimer Analyst forecast on IT:1BSX
Suraj Kalia
Oppenheimer
Oppenheimer
€73.83
Buy
80.07%
Upside
Reiterated
07/30/26
Oppenheimer Keeps Their Buy Rating on Boston Scientific (BSX)
Leerink Partners Analyst forecast on IT:1BSX
Mike Kratky
Leerink Partners
Leerink Partners
€64.28→€52.12
Buy
27.11%
Upside
Reiterated
07/30/26
Boston Scientific price target lowered to $60 from $74 at LeerinkBoston Scientific price target lowered to $60 from $74 at Leerink
J.P. Morgan Analyst forecast on IT:1BSX
Robbie Marcus
J.P. Morgan
J.P. Morgan
€69.49→€48.64
Buy
18.64%
Upside
Assigned
07/30/26
Boston Scientific price target lowered to $56 from $80 at JPMorganBoston Scientific price target lowered to $56 from $80 at JPMorgan
Evercore ISI Analyst forecast on IT:1BSX
Vijay Kumar
Evercore ISI
Evercore ISI
€56.46→€47.77
Buy
16.52%
Upside
Reiterated
07/30/26
Boston Scientific price target lowered to $55 from $65 at Evercore ISIBoston Scientific price target lowered to $55 from $65 at Evercore ISI
Robert W. Baird Analyst forecast on IT:1BSX
David Rescott
Robert W. Baird
Robert W. Baird
€55.59→€48.64
Buy
18.64%
Upside
Reiterated
07/30/26
Boston Scientific price target lowered to $56 from $64 at BairdBoston Scientific price target lowered to $56 from $64 at Baird
TD Cowen Analyst forecast on IT:1BSX
Josh Jennings
TD Cowen
TD Cowen
€52.98→€48.64
Buy
18.64%
Upside
Reiterated
07/30/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC) and Boston Scientific (NYSE: BSX)
Canaccord Genuity Analyst forecast on IT:1BSX
William Plovanic
Canaccord Genuity
Canaccord Genuity
€60.8→€57.33
Buy
39.82%
Upside
Reiterated
07/30/26
Boston Scientific price target lowered to $66 from $70 at CanaccordBoston Scientific price target lowered to $66 from $70 at Canaccord
UBS Analyst forecast on IT:1BSX
Patrick Wood
UBS
UBS
€64.28→€58.2
Buy
41.94%
Upside
Reiterated
07/30/26
Morgan Stanley Reaffirms Their Buy Rating on Boston Scientific (BSX)
Needham Analyst forecast on IT:1BSX
Michael Matson
Needham
Needham
€49.51
Buy
20.76%
Upside
Reiterated
07/29/26
Analysts Offer Insights on Healthcare Companies: Rezolute (NASDAQ: RZLT) and Boston Scientific (NYSE: BSX)
Wells Fargo Analyst forecast on IT:1BSX
Larry Biegelsen
Wells Fargo
Wells Fargo
€47.77→€43.43
Hold
5.93%
Upside
Reiterated
07/29/26
Analysts Are Neutral on Top Healthcare Stocks: Boston Scientific (BSX), Capricor Therapeutics (CAPR)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Boston Scientific

3 Months
Marie ThibaultBTIG
Success Rate
28/40 ratings generated profit
70%
Average Return
+2.12%
Copying Marie Thibault's trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +2.12% per trade.
1 Year
Jayson BedfordRaymond James
Success Rate
39/53 ratings generated profit
74%
Average Return
+12.29%
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 73.58% of your transactions generating a profit, with an average return of +12.29% per trade.
2 Years
Jayson BedfordRaymond James
Success Rate
41/53 ratings generated profit
77%
Average Return
+23.25%
Copying Jayson Bedford's trades and holding each position for 2 Years would result in 77.36% of your transactions generating a profit, with an average return of +23.25% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1BSX Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
30
36
25
18
8
Buy
67
52
45
47
34
Hold
1
3
3
4
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
98
91
73
69
44
In the current month, 1BSX has received 42 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 1BSX average Analyst price target in the past 3 months is 54.21.
Each month's total comprises the sum of three months' worth of ratings.

1BSX Financial Forecast

1BSX Earnings Forecast

Next quarter’s earnings estimate for 1BSX is €0.70 with a range of €0.69 to €0.73. The previous quarter’s EPS was €0.75. 1BSX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year 1BSX has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1BSX is €0.70 with a range of €0.69 to €0.73. The previous quarter’s EPS was €0.75. 1BSX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year 1BSX has Performed in-line its overall industry.

1BSX Sales Forecast

Next quarter’s sales forecast for 1BSX is €4.57B with a range of €4.51B to €4.61B. The previous quarter’s sales results were €4.73B. 1BSX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year 1BSX has Performed in-line its overall industry.
Next quarter’s sales forecast for 1BSX is €4.57B with a range of €4.51B to €4.61B. The previous quarter’s sales results were €4.73B. 1BSX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year 1BSX has Performed in-line its overall industry.

1BSX Stock Forecast FAQ

What is IT:1BSX’s average 12-month price target, according to analysts?
Based on analyst ratings, Boston Scientific’s 12-month average price target is 54.21.
    What is IT:1BSX’s upside potential, based on the analysts’ average price target?
    Boston Scientific has 32.21% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Boston Scientific a Buy, Sell or Hold?
          Boston Scientific has a consensus rating of Strong Buy, which is based on 21 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Boston Scientific’s share price target?
            The average share price target for Boston Scientific is 54.21. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €77.30 ,and the lowest forecast is €43.43. The average share price target represents 32.21% Increase from the current price of €41.
              What do analysts say about Boston Scientific?
              Boston Scientific’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Streets Analysts.
                How can I buy shares of Boston Scientific?
                To buy shares of IT:1BSX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.